Board of directors

Dr. Marian Borovsky, Chairman, non-executive member of the Board of Directors

As Group General Counsel and a member of the Executive Committee, led Actelion’s legal department for 17 years from its startup phase until its acquisition by Johnson & Johnson in 2017. Thereafter, held interim positions as Group General Counsel/Chief Legal Officer with Idorsia Pharmaceuticals AG (March – October 2022) and at Swiss Rockets AG/Rocketvax AG (May – July 2021).

Günter Graubach, Founder & Executive Member of the Board of Directors, Chief Corporate Development Officer (CCDO)

Former Chairman of the board of directors of Curatis (2012-April 2024) and Curatis’ Chief Executive Officer (until 2011). Held various commercial management positions at Speciality European Pharma (now Contura), MyoContract (now Santhera Pharmaceuticals), Hoffmann-La Roche in Switzerland, USA, and Latin America. Graduated with a Master’s Degree in Business from the University of Lyon, France and a post graduate degree in Economics from the University of Constance, Germany.

Dr. Roland Rutschmann, Executive Member of the Board of Directors, Chief Executive Office (CEO)

Former board member of Curatis AG (since 2010) and Chief Executive Officer of Curatis AG (2011-2019). Previously he held positions as Vice President/General Manager at Orphan Europe in Paris France and was in this function member of the Executive Management of Recordati Group (Milan, Italy), and was Regional Vice President/General Manager and Vice President Strategic Marketing Europe at Actelion. Mr. Rutschmann also held various management positions in marketing and sales for Hoffmann-La Roche and Warner-Lambert in Switzerland, the Netherlands and Germany. Mr. Rutschmann holds a PhD in cell biology/immunology from the University of Basle and completed management programs at INSEAD.

Dr. Silvio Inderbitzin, non-executive member of the Board of Directors

Dr. Silvio Inderbitzin is a member of the Board of Directors and shareholder in the Company. Dr. Inderbitzin has held multiple senior positions in the pharmaceutical industry during the last 20 years. With his origin in pharmaceutical manufacturing, he also served as Head of Quality Assurance and was responsible for product release as a Qualified Person at Spirig Pharma AG. He was later elected to the position of Technical Director of Spirig Pharma AG and served in the Corporate Management Team, ultimately joining the board of directors and becoming co-owner of the privately held 450 employee company. Prior to the successful sale of the Spirig Pharma AG, he served as CEO and was responsible for its foreign subsidiaries. He is an active investor and board member of several life science and MedTech companies as well as startups. Dr. Inderbitzin studied pharmacy at the University of Berne, holds a Ph.D. in Pharmacology from the University of Zurich/ETH, and obtained an Executive MBA from the University of St. Gallen.